NASDAQ$AXSM
Axsome Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Axsome Therapeutics reported Q1 2025, revenue of $75M, net loss of $59.4M, diluted EPS of $-1.22.
For Q1 2025, Axsome Therapeutics reported revenue of $75M, a net loss of $59.4M, diluted EPS was $-1.22. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Q1 2025 revenue $75M.
- Net loss $59.4M.
- Diluted EPS $-1.22.
Headline financials
Revenue & EPS history
Axsome · Revenue · Quarterly
$121M
Revenue by segment
Axsome · $57.8M total across 2 segments · Q3 2023
- AUVELITY$37.7M—65.2%
- SUNOSI$20.1M+19.6%34.8%
Forward guidance
Growth and biotech filers emphasize pipeline, commercial ramp, and cash runway rather than near-term GAAP profitability targets.
Tailwinds
- Product revenue growth or launch momentum.
- Partnership and platform expansion.
- Balance sheet liquidity for R&D.
Headwinds
- Operating losses until scale is reached.
- R&D and SG&A spend ahead of revenue.
- Regulatory and reimbursement risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-1.0%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+1.7%
Avg return
30 days after
51%
21 / 41 earnings
Positive
+12.9%
Q1 2022
Best reaction
-53.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.1% | +5.3% | +13.0% | |
| Q4 2025 | -4.7% | -10.8% | -11.9% | |
| Q3 2025 | +1.9% | +2.3% | +9.5% | |
| Q1 2025 | +3.7% | -4.0% | -3.6% | |
| Q4 2024 | -2.3% | +5.0% | -3.7% | |
| Q3 2024 | +7.5% | +2.4% | +3.7% | |
| Q2 2024 | +1.3% | -1.6% | +13.2% | |
| Q1 2024 | +2.9% | -3.1% | -0.9% | |
| Q4 2023 | -11.5% | -14.9% | -12.9% | |
| Q3 2023 | -3.1% | -11.9% | +6.5% | |
| Q2 2023 | -1.5% | -5.5% | +10.7% | |
| Q1 2023 | +4.1% | +7.1% | +2.4% | |
| Q4 2022 | +11.7% | +6.9% | +2.3% | |
| Q3 2022 | +11.2% | +3.4% | +36.9% | |
| Q2 2022 | +11.7% | +6.8% | +41.3% | |
| Q1 2022 | +12.9% | -6.1% | -24.3% | |
| Q4 2021 | +11.9% | +6.4% | +47.2% | |
| Q3 2021 | +1.4% | -2.3% | -12.6% | |
| Q2 2021 | -53.5% | -55.3% | -48.9% | |
| Q1 2021 | +0.1% | +2.6% | +11.5% | |
| Q4 2020 | +3.6% | -3.5% | -15.9% | |
| Q3 2020 | -9.7% | -6.3% | +7.1% | |
| Q2 2020 | -0.6% | +1.2% | -7.3% | |
| Q1 2020 | -2.8% | -7.9% | -15.7% | |
| Q4 2019 | -16.8% | -38.7% | -23.8% | |
| Q3 2019 | -1.2% | -4.6% | +76.4% | |
| Q2 2019 | +2.2% | +11.0% | -0.5% | |
| Q1 2019 | +7.2% | +10.7% | +12.2% | |
| Q4 2018 | +4.6% | +24.3% | +29.2% | |
| Q3 2018 | -15.8% | -28.1% | -24.7% | |
| Q2 2018 | -1.9% | -8.6% | +27.6% | |
| Q1 2018 | +1.5% | +3.0% | +4.5% | |
| Q4 2017 | +2.6% | +6.5% | -8.4% | |
| Q3 2017 | -4.1% | +1.0% | -0.5% | |
| Q2 2017 | -5.0% | -12.6% | -19.3% | |
| Q1 2017 | -1.2% | -1.2% | -4.8% | |
| Q4 2016 | -4.1% | +6.1% | -27.6% | |
| Q3 2016 | +0.7% | +4.1% | -17.8% | |
| Q2 2016 | -1.4% | -3.4% | -1.6% | |
| Q1 2016 | -1.4% | -3.4% | -1.6% | |
| Q4 2015 | -10.0% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro